Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
BIOLASE, Inc. (NASDAQ: BIOL) has completed a bought deal offering of 14 million shares at $1.03 per share, raising approximately $14.4 million. This increase in cash brings their total to over $40 million, facilitating the execution of their growth strategy. The offering was met with strong interest from healthcare-focused institutional investors. Joint-bookrunning managers included Maxim Group LLC, The Benchmark Company, and Colliers Securities LLC. The shares were offered under a previously effective registration statement with the SEC.
BIOLASE, Inc. (NASDAQ: BIOL) has entered into an underwriting agreement with Maxim Group LLC to sell 14,000,000 shares of common stock at $1.03 per share. This offering is expected to raise approximately $14.4 million before expenses. The offering's closing is anticipated around February 10, 2021, pending customary closing conditions. This stock sale is part of a shelf registration statement filed with the SEC. BIOLASE is known for its innovative dental laser systems that enhance patient care and clinical outcomes.
BIOLASE, Inc. (NASDAQ: BIOL) has regained compliance with NASDAQ's minimum bid price requirement, confirming its closing bid price has been at least $1.00 for ten consecutive days as of February 3, 2021. This follows a prior notification from NASDAQ in December 2019 regarding a price drop. Consequently, the company has canceled its Special Meeting of Stockholders scheduled for February 16, 2021, and will not pursue a reverse stock split at this time. BIOLASE specializes in developing laser systems for dental and medical applications.
BIOLASE, Inc. (NASDAQ: BIOL) urges stockholders to vote for a proposed 1-for-25 reverse stock split at the reconvened special meeting on February 16, 2021. Insufficient votes were recorded at the initial meeting held on January 22, 2021. The record date for eligible voters changed to January 25, 2021. Stockholders can vote online or by phone to ensure representation. BIOLASE, a leader in dental lasers, has sold over 41,200 laser systems globally, enhancing patient care in dentistry and medicine.
BIOLASE, Inc. (NASDAQ: BIOL) has announced preliminary revenue results for Q4 2020, estimating revenues between $8.2 million and $8.5 million, reflecting a sequential growth of 26-31%. The company reported a cash position of approximately $25 million to support its growth strategy. Notably, 78% of sales came from new users, and U.S. revenue surpassed the previous year's fourth quarter, despite challenges posed by COVID-19. BIOLASE launched initiatives like the Waterlase Endo Academy to enhance its market presence.
On January 12, 2021, BIOLASE announced a partnership with Dental Care Alliance (DCA) to enhance laser adoption in dental practices across the U.S. DCA, a major dental support organization with over 330 affiliated offices, will implement BIOLASE's EpicX and Epic Hygiene lasers, aimed at improving patient care and safety. With more than 100 systems already sold to DCA this year, BIOLASE anticipates widespread deployment throughout 2021. This agreement highlights the growing demand for advanced dental technologies that provide less invasive treatment options.
BIOLASE, Inc. (NASDAQ: BIOL) announced that Todd Norbe and John Beaver will provide an overview of the company at the H.C. Wainwright BIOCONNECT 2021 Investor Conference from January 11-14, 2021. A recorded presentation will be available on-demand starting January 11 at 6:00 a.m. ET on BIOLASE's website. Investors can also arrange virtual one-on-one meetings during the event. BIOLASE is a leader in dental lasers, with over 41,200 systems sold globally, offering innovative laser solutions for various dental procedures.
BIOLASE, a leader in dental lasers, announced a collaboration with BMW Performance Center West for the 2021 Waterlase Exclusive Trial Program. Dentists can participate in a special two-day training and use the Waterlase dental laser at no cost for 45 days. This initiative includes a chance for dentists to win a BMW vehicle lease. The promotional program aims to engage dentists by merging cutting-edge dental technology with a premium driving experience. The event series begins in January 2021.
BIOLASE (NASDAQ: BIOL) will present at the 13th annual LD Micro Main Event investor conference on December 14, 2020, at 9:40 AM PST / 12:40 PM EST. The presentation will be led by President and CEO Todd Norbe and Executive Vice President, CFO and COO John Beaver. This year's conference features a unique format with 10-minute presentations followed by Q&A sessions. This event aims to engage both executives and investors globally.
To learn more, view BIOLASE's profile.
BIOLASE announced the launch of the Waterlase Endo Academy on Nov. 14, 2020, aimed at improving patient outcomes and profitability among endodontists through advanced technology. The academy offers a community for peer-led learning and sharing best practices, featuring mentorship, online meetings, and in-person training. The Waterlase dental laser technology enhances efficiency and patient care, allowing for various dental procedures. BIOLASE has sold over 41,200 laser systems worldwide, underscoring its leadership in dental lasers.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
